

International AIDS Society supported by the Bill & Melinda Gates Foundation

PrEP IMPLEMENTATION POLICY FORUM
Developing Country-Level Preparation and Capacity for PrEP Implementation

Sunday 22 July 2007, 4pm-7pm
Ballroom 1, Four Points by Sheraton, 161 Sussex Street, Sydney, Australia

Meeting objectives

- (1) Provide guidance on anticipating and translating results from PrEP trials to different country situations, epidemiology and local circumstances
- (2) Discuss possible strategies for implementing PrEP in different country settings including:
 - potential need for bridging studies to ensure findings are relevant to country epidemics
 - assess feasibility of implementing a PrEP programme (using TDF and/or Truvada)

Agenda

Meeting Chairs: Craig McClure, Chief Executive, International AIDS Society, Switzerland
Renee Ridzon, Bill & Melinda Gates Foundation, USA

4.00pm Welcome, introductions, meeting objectives

4.20pm **Translating research into policy**

Presentation 1: Lynn Paxton and Dawn Smith, US Centers for Disease Control and Prevention (CDC): country scenario planning and modelling

4.50pm Presentation 2: Research to policy: example from male circumcision implementation

5.00pm Q&A moderated by Renee Ridzon

5.15pm Break

5.30pm **Country level preparedness: government perspectives**

Contribution from Ministry of Health representatives

Discussion facilitated by Craig McClure

6.20pm **Roundtable discussion**

- normative agencies on country preparedness guidelines
- perspectives from civil society
- perspectives from industry
- learning from microbicides delivery models: IPM

6.40pm **Way forward: action planning**

7:00pm Close

International AIDS Society
Chemin de l'Avanchet 33
PO Box 20, CH-1216 Cointrin
Geneva Switzerland

Tel: +41 22 710 08 00
Fax: +41 22 710 08 99

info@iasociety.org
www.iasociety.org

IAS PrEP IMPLEMENTATION POLICY FORUM
Sunday 22 July 2007, 4PM-7.00PM, Sydney, Australia

Questions to stakeholders

Questions to MOH

1. Assume that the first PrEP trial shows a 70% reduction in HIV infection using single daily TDF - how might you use PrEP in your country e.g. would you target PrEP at high-risk populations or promote general accessibility?
2. What principal obstacles will you have to overcome in implementing PrEP if proven effective?

Question to industry

- If PrEP is shown to work, what impact do you anticipate, e.g. what level of demand for TDF and/or Truvada for use as PrEP do you estimate? Do you have the capacity to scale-up production if needed?

Question to normative agencies

- What is your agency's role in preparing and supporting countries in the implementation of PrEP if proven effective? How can you assist resource-limited countries to develop structural capacity for implementation of proven biomedical prevention technologies?

Question to civil society

- What educational tools and media strategies are in place or needed to deliver PrEP in the community?

Question to investigators and sponsors of HIV prevention research

- What will you (or should you) do in preparation for PrEP clinical trial results?

Participant list

1. Ward Cates, Family Health International (FHI), USA
2. Peter Cherutich, Ministry of Health, Kenya
3. Katchit Choopanya, Bangkok Tenofovir Study Group, Thailand
4. Kevin de Cock, World Health Organisation (WHO) Switzerland
5. Carl Diffenbach, US National Institutes of Health (NIH), USA
6. Telmo Fernandez, PrEP Trial, Ecuador
7. Pedro Goicochea, Impacta, Peru
8. Bob Grant, University of California San Francisco (UCSF), USA
9. Yasmin Halima, International AIDS Society (IAS), USA
10. Cate Hankins, UNAIDS, Switzerland
11. Mina Hosseinipour, Investigator, Malawi
12. Mathias Joshua, Ministry of Health, Malawi
13. Somyot Kittimunkong, Ministry of Public Health, Thailand
14. Rodney Kort, IAS, Switzerland

International AIDS Society
Chemin de l'Avanchet 33
PO Box 20, CH-1216 Cointrin
Geneva Switzerland

Tel: +41 22 710 08 00
Fax: +41 22 710 08 99

info@iasociety.org
www.iasociety.org

15. Craig McClure, IAS, Switzerland
16. Michael Martin, US CDC, Thailand
17. Veronica Miller, Collaborative Forum for HIV Research, USA
18. Biziwick Mwale, National AIDS Commission, Malawi
19. Lynn Paxton, US Centers for Disease Control and Prevention (CDC), USA
20. Renee Ridzon, Bill & Melinda Gates Foundation, USA
21. Maria Elena Rojas, National AIDS Program Director, Ecuador
22. Jim Rooney, Gilead, USA
23. Zeda Rosenberg, International Partnership for Microbicides (IPM), USA
24. Clifford Samuel, Gilead, USA
25. Dawn Smith, CDC, USA
26. Shaleena Theophilus, Global Campaign for Microbicides (GCM), Canada
27. Morenike Ukpong, HIV Vaccine and Microbicide Advocacy Group, Nigeria
28. Suphak Vanichseni, Bangkok Tenofovir Study Group, Thailand
29. Mitchell Warren, AIDS Vaccine Advocacy Coalition (AVAC), USA

Yasmin Halima, IAS, July 2007